We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent Ovarian Cancer

This study has been terminated.
(Due to unacceptable non-dose limiting toxicities, excessive treatment delays and limited clinical responses.)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00317434
First Posted: April 24, 2006
Last Update Posted: December 15, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
GlaxoSmithKline
Information provided by:
University of Alabama at Birmingham
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: April 2007
  Primary Completion Date: March 2007 (Final data collection date for primary outcome measure)
Publications: